WHO ICTRP trial
Study to investigate the efficacy of QGC001 in patients affected by high blood…
EUCTR2014-003071-37-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2014-003071-37-FR |
|---|---|
| Public title | Study to investigate the efficacy of QGC001 in patients affected by high blood pressure. |
| Scientific title | Multicenter, randomized, double-blind, two-period, placebo controlled, forced-titration proof of concept crossover study to compare QGC001 with placebo in patients with grade I or II essential hypertension |
| Primary sponsor | Quantum Genomics |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France |
| Conditions | Hyperactivity of the brain renin-angiotensin system participates to the development and maintenance of essential Hypertension MedDRA version: 18.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class… |
| Interventions | Product Code: QGC001 Pharmaceutical Form: Capsule Other descriptive name: QGC001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule Route of administration of… |
| Registration date | Jun 26, 2015 |
| Target size | 36 |
| Secondary IDs | QGC001/2QG1 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: